Oxford BioTherapeutics

OverviewSuggest Edit

Oxford BioTherapeutics (OBT) is focused on the development of targeted medicines in the field of cancer. The company has signed strategic partnerships with the leading antibody companies Medarex, Biosite and Amgen to build a broad pipeline of novel antibody therapeutics using its unique OGAP® (Oxford Genome Anatomy Project) platform. OGAP® is one of the world’s largest proprietary human protein databases which contains and combines proteomic and genomic data with related clinical information. OBT also intends to develop companion diagnostics for selected antibody programmes. The company expects to improve disease management and treatment outcomes by integrating diagnostics into product development and commercialisation activities.

TypePrivate
Founded2004
HQMilton, GB
Websiteoxfordbiotherapeutics.com

Latest Updates

Employees (est.) (Jun 2019)26(-3%)
Revenue (FY, 2017)£4.5 M(+51%)

Key People/Management at Oxford BioTherapeutics

Chris Hibberd

Chris Hibberd

Non Executive Director - UK

Oxford BioTherapeutics Office Locations

Oxford BioTherapeutics has offices in Milton and San Jose
Milton, GB (HQ)
Milton Park Innovation Centre 99 Park Dr
San Jose, US
5941 Optical Ct
Show all (2)

Oxford BioTherapeutics Financials and Metrics

Summary Metrics

Founding Date

2004

Oxford BioTherapeutics total Funding

$21.6 m

Oxford BioTherapeutics latest funding size

$10 m

Time since last funding

4 years ago

Oxford BioTherapeutics investors

Oxford BioTherapeutics's latest funding round in July 2015 was reported to be $10 m. In total, Oxford BioTherapeutics has raised $21.6 m
Show all financial metrics

Oxford BioTherapeutics Revenue

Oxford BioTherapeutics's revenue was reported to be £4.55 m in FY, 2017
GBP

Revenue (FY, 2017)

4.5m

Net income (FY, 2017)

(2.3m)

EBITDA (FY, 2017)

(3.0m)

EBIT (FY, 2017)

(3.2m)

Cash (31-Dec-2017)

4.3m
GBPFY, 2006FY, 2007FY, 2008FY, 2009FY, 2015FY, 2016FY, 2017

Revenue

427.3k293.8k429.5k2.0m3.0m4.5m

Cost of goods sold

82.0k125.3k117.2k157.4k480.4k438.6k

Gross profit

345.3k176.7k272.1k1.5m2.6m

Gross profit Margin, %

81%60%63%76%85%
GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

79.3k110.4k37.8k550.7k3.7k577.2k9.2m4.0m2.1m1.2m2.6m821.4k3.1m4.3m

Accounts Receivable

135.3k15.2k33.4k727.2k958.6k1.2m2.6m2.9m168.5k25.5k3.6k

Inventories

19.3k8.1k8.8k14.1k18.6k17.2k9.7k9.8k9.8k

Current Assets

174.7k250.4k178.3k829.7k364.3k971.6k9.9m5.0m3.4m3.8m5.5m2.4m4.4m5.7m
GBPFY, 2006FY, 2007FY, 2008FY, 2009FY, 2015FY, 2016FY, 2017

Net Income

(546.5k)(1.3m)(1.2m)(1.6m)(5.6m)(6.0m)(2.3m)

Income Taxes Paid

1.2m964.4k
GBPY, 2017

Revenue/Employee

142.4k

Financial Leverage

-2 x
Show all financial metrics

Oxford BioTherapeutics News and Updates

Oxford BioTherapeutics Receives US FDA IND Clearance for OBT076

OXFORD, England and SAN JOSE, Calif., December 21, 2018 /PRNewswire/ -- An experimental first in class ADC medicine for high risk Her2 negative breast cancer, gastric, lung, bladder and ovarian cancer patients - US phase I clinical trial to be initiated. Oxford BioTherapeutics Ltd....

Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million

SHANGHAI and OXFORD, the United Kindom, Dec. 10, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing and Oxford BioTherapeutics Ltd. ("OBT"),...

Oxford BioTherapeutics Frequently Asked Questions

  • When was Oxford BioTherapeutics founded?

    Oxford BioTherapeutics was founded in 2004.

  • Who are Oxford BioTherapeutics key executives?

    Oxford BioTherapeutics's key executives are Chris Hibberd.

  • How many employees does Oxford BioTherapeutics have?

    Oxford BioTherapeutics has 26 employees.

  • What is Oxford BioTherapeutics revenue?

    Latest Oxford BioTherapeutics annual revenue is £4.5 m.

  • What is Oxford BioTherapeutics revenue per employee?

    Latest Oxford BioTherapeutics revenue per employee is £174.8 k.

  • Who are Oxford BioTherapeutics competitors?

    Competitors of Oxford BioTherapeutics include Ajinomoto Althea, Ambys Medicines and UniQure.

  • Where is Oxford BioTherapeutics headquarters?

    Oxford BioTherapeutics headquarters is located at Milton Park Innovation Centre 99 Park Dr, Milton.

  • Where are Oxford BioTherapeutics offices?

    Oxford BioTherapeutics has offices in Milton and San Jose.

  • How many offices does Oxford BioTherapeutics have?

    Oxford BioTherapeutics has 2 offices.